Elaina M. Gartner

2.8k total citations · 2 hit papers
40 papers, 1.7k citations indexed

About

Elaina M. Gartner is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Elaina M. Gartner has authored 40 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 20 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Elaina M. Gartner's work include Bladder and Urothelial Cancer Treatments (19 papers), Urinary and Genital Oncology Studies (17 papers) and Cancer Treatment and Pharmacology (6 papers). Elaina M. Gartner is often cited by papers focused on Bladder and Urothelial Cancer Treatments (19 papers), Urinary and Genital Oncology Studies (17 papers) and Cancer Treatment and Pharmacology (6 papers). Elaina M. Gartner collaborates with scholars based in United States, Canada and Spain. Elaina M. Gartner's co-authors include Amal Melhem‐Bertrandt, Daniel P. Petrylak, Jonathan E. Rosenberg, Elisabeth I. Heath, Peter H. O’Donnell, Arjun Vasant Balar, Noah M. Hahn, Bradley A. McGregor, Evan Y. Yu and Juan Pinelli and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Elaina M. Gartner

40 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2019 435 citations Jonathan E. Rosenberg, Peter H. O’Donnell et al. Journal of Clinical Oncology profile →
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →

Peers

Elaina M. Gartner

ONCOL

SURGE

IMMUN

PRM

Matt D. Galsky United States

Kiyotaka Okuno Japan

Saeed Rafii United Kingdom

Michail Doukas Netherlands

Katsunari Yane Japan

Henning Wege Germany

Taigo Kato Japan

Hideya Takeuchi Japan

Autumn J. McRee United States

Mitsuharu Nomoto Japan

Matt D. Galsky United States

Elaina M. Gartner

982 ×1.0

ONCOL

1.0k ×1.5

SURGE

445 ×1.0

196 ×0.6

IMMUN

407 ×1.4

PRM

Citations per year, relative to Elaina M. Gartner Elaina M. Gartner (= 1×) peers Matt D. Galsky

Countries citing papers authored by Elaina M. Gartner

Since Specialization

Citations

This map shows the geographic impact of Elaina M. Gartner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elaina M. Gartner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elaina M. Gartner more than expected).

Fields of papers citing papers by Elaina M. Gartner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elaina M. Gartner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elaina M. Gartner. The network helps show where Elaina M. Gartner may publish in the future.

Co-authorship network of co-authors of Elaina M. Gartner

This figure shows the co-authorship network connecting the top 25 collaborators of Elaina M. Gartner. A scholar is included among the top collaborators of Elaina M. Gartner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elaina M. Gartner. Elaina M. Gartner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gartner, Elaina M., et al.. (2022). Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer. Cancer Chemotherapy and Pharmacology. 90(5). 399–408. 8 indexed citations

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →

Takahashi, Shunji, Motohide Uemura, Tomokazu Kimura, et al.. (2019). A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Investigational New Drugs. 38(4). 1056–1066. 65 indexed citations

Rosenberg, Jonathan E., Peter H. O’Donnell, Arjun Vasant Balar, et al.. (2019). Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology. 37(29). 2592–2600. 435 indexed citations breakdown →

Phillips, Tycel, Paul M. Barr, Steven I. Park, et al.. (2018). A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs. 37(2). 297–306. 57 indexed citations

Rosenberg, Jonathan E., Elisabeth I. Heath, Peter H. O’Donnell, et al.. (2018). EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.. Journal of Clinical Oncology. 36(15_suppl). TPS4590–TPS4590. 9 indexed citations

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2018). Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).. Journal of Clinical Oncology. 36(15_suppl). 4504–4504. 33 indexed citations

Rosenberg, Jonathan E., Elisabeth I. Heath, Raymond P. Perez, et al.. (2016). Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 27. vi273–vi273. 9 indexed citations

Tannir, Nizar M., Andres Forero‐Torres, Radhakrishnan Ramchandren, et al.. (2014). Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investigational New Drugs. 32(6). 1246–1257. 97 indexed citations

10.

Tolaney, Sara M., Howard A. Burris, Elaina M. Gartner, et al.. (2014). Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 151–161. 49 indexed citations

11.

Clemens, Michael, Oleg Gladkov, Elaina M. Gartner, et al.. (2014). Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 171–179. 67 indexed citations

12.

Mueller, Kelly, et al.. (2013). Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells. Journal of Surgical Research. 185(1). 231–239. 38 indexed citations

13.

Gartner, Elaina M., Paula Silverman, Michael S. Simon, et al.. (2011). A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Research and Treatment. 131(3). 933–937. 53 indexed citations

14.

Tolaney, SM, Howard A. Burris, Elaina M. Gartner, et al.. (2011). P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.. Cancer Research. 71(24_Supplement). P1–17. 1 indexed citations

15.

Vonderheide, Robert H., Patricia LoRusso, Magi Khalil, et al.. (2010). Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells. Clinical Cancer Research. 16(13). 3485–3494. 234 indexed citations

16.

Adams, Laurel M., Brendan M. Johnson, John W. Bauman, et al.. (2010). Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemotherapy and Pharmacology. 67(4). 783–790. 5 indexed citations

17.

Gartner, Elaina M., Angelika M. Burger, & Patricia LoRusso. (2010). Poly(ADP-Ribose) Polymerase Inhibitors. The Cancer Journal. 16(2). 83–90. 27 indexed citations

18.

Herfarth, Klaus, Mark R. Wick, Helen Marshall, et al.. (1997). Absence ofTP53 alterations in pheochromocytomas and medullary thyroid carcinomas. Genes Chromosomes and Cancer. 20(1). 24–29. 36 indexed citations

19.

Kleeberg, Ulrich R., et al.. (1987). Megestrolazetat versus Medroxyprogesteronazetat in der Behandlung metastasierender Mammakarzinome. Oncology Research and Treatment. 10(2). 104–106. 9 indexed citations

20.

Schindler, Ursula, Elaina M. Gartner, & E. Betz. (1973). Energy-Rich Metabolites and EEG in Hypoxia and in Hypercapnia. Advances in experimental medicine and biology. 37A. 233–238. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact